Partnering Opportunities & Translational Funding for Neurofibromatosis Neurofibromatosis (NF): -...

 Partnering Opportunities & Translational Funding for Neurofibromatosis

Neurofibromatosis (NF):- A rare disease - 1:3,000- Tumor suppressor genes – NF1, NF2- Brain/nerve tumors; benign & malignant- Learning disabilities, bone dysplasia, pain

NF Research Today:- Candidate drug targets - Preclinical models - GEMs- Trial pipeline- 44 site NF Clinic Network- NF BioBank & Patient Registry

Why Should You Look at NF?- Cancer crossover - Ras – broad relevance- Growing commercial interest in rare diseases

1

2

CTF NF Translational Pipeline Opportunities

engageindustry

Drug Discovery Initiative Clinical Research Award $15K, $30K vitro/vivo screencandidate NF Rx

$100K – pilot clinical trial or biomarker study

3

Opportunities for Collaboration with CTF & NF ResearchFUNDING:Drug Discovery Initiative Awards $15K & $30K

- Deadlines Feb & August - 3 page app - fast turnaroundClinical Research Awards $100K - LOI deadline Spring 2011

INDUSTRY/DRUGS:- Growing NF interest – CTF at BIO, FasterCures, etc.- Industry advisors on RAB – AstraZeneca, Lilly, Plexxikon ...

CELLS, ANIMAL MODELS, TISSUES:- Online DDI Toolbox; NF BioBank- CTF MA funded sites e.g. Harvard, MIT, Whitehead, Children’s,

Tufts

CLINICAL TRIALS: Clinical Trials Consortium, Patient Registry

NETWORKING: 2011 NF Conference, Jackson Hole, WY June 11-14. ____________________________________________________Kim Hunter-Schaedle, Ph.D. CSO, Children’s Tumor Foundation

khs@ctf.org www.ctf.org - http://www.partneringforcures.org/2010_innovators/29_neurofib.html